-
South Africa vows firm response to anti-migrant violence
-
New Zealand make England toil as Stokes returns for series decider
-
Poland, Ukraine hold key Gdansk conference without Zelensky
-
Americans impacted by climate change demand answers from lawmakers
-
Massive police deployment blocks Kenya protest anniversary
-
Heat-struck Italians cool off in ancient stone 'trulli'
-
Court orders TotalEnergies to account for clients' emissions
-
French teaching unions call strike over 'unacceptable' heat
-
Stocks rally on renewed AI optimism, oil price declines
-
US Fed's preferred inflation gauge hits fresh three-year high
-
Venezuela twin quakes kill at least 164 with many trapped under rubble
-
Dominant Osaka cruises into Bad Homburg semis
-
IOC votes to continue ski mountaineering for 2030 Games
-
New Zealand frustrate England as Stokes returns for series decider
-
Stocks rally on AI optimism after Micron's blowout forecast
-
Poland, Ukraine tone down dispute at reconstruction conference
-
Tunisia's short-lived World Cup experience lays bare deep dysfunctions
-
At-risk UK elderly bid to stay cool as heatwave bears down
-
'Everything collapsed': Venezuela region hit hardest by quakes cries for help
-
'Need each other': Macron hosts Meloni after Trump rift
-
Kenya police turn out in force on protest anniversary
-
Stokes straight back into the action as New Zealand bat in 3rd Test
-
Baking heatwave gives Europe no respite
-
Amazon pledges additional $13 bn in India AI investment
-
Trump climate pushback spurs courtroom battles, report says
-
Struggling VW to sell majority stake in marine engine unit
-
Kenya police in massive show of force on protest anniversary
-
Seoul stocks soar in Asia tech rally after Micron's blowout forecast
-
USA, Germany in control as Dutch eye World Cup knockouts
-
Trump-linked resort shines light on Albania's 'stolen' land
-
Violence feared as Kenya marks protest anniversary
-
French aversion to air conditioning melts as homes sizzle
-
Ukraine recovery summit opens, overshadowed by Kyiv-Warsaw row
-
Municipal misery weighs on looming S.African elections
-
Chad sees influx of drone victims from Sudan
-
Hong takes blame as South Korea's World Cup hopes fade
-
'We shut up big mouths,' says South Africa's World Cup coach Broos
-
Brazil advance at World Cup, history for South Africa, Canada, Bosnia
-
Mothers search, men weep amid debris of Venezuela quakes
-
Confirmation still a rite of passage in Denmark but less Christian
-
South Africa stun South Korea to make World Cup history
-
Seoul stocks soar in Asia tech rally after Micron blowout forecast
-
Clarke fears Scotland 'probably going home' after Brazil World Cup loss
-
Moriyasu vows Japan will play to win and top group against Sweden
-
Secret cameras, mics and AI reveal rare Cambodia wildlife
-
Beloved spiritual utopia under threat in Modi's India
-
Bulgaria's milk farmers falter in former yogurt empire
-
Ancelotti hails Vinicius as Brazil march on at World Cup
-
Trump opens US 250th birthday party with rally-style speech
-
Morocco have 'ingredients' of World Cup winners, says coach Ouahbi
Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21
HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today announced that Kraig Higginson, Chief Executive Officer of Aspire, will be presenting at the upcoming Sidoti Virtual Investor Conference on May 21 at 2:30 PM Eastern. Investors and other interested individuals may access the virtual presentation here: https://sidoti.zoom.us/webinar/register/WN_q62DwzilROyKt-kOh_GJDQ
One-on-One Meetings
Inspire will also host virtual one-on-ones with investors on Wednesday, May 21 and Thursday, May 22, 2025. To register for the presentation or one-on ones, visit https://sidoti.com/events.
A replay of the presentation will be available on the investor relations section of Inspire's website at https://ir.aspirebiolabs.com/events/
About Aspire Biopharma, Inc.
Headquartered in Humacao, Puerto Rico, Aspire Biopharma has developed a disruptive technology through a Novel Soluble Formulation which addresses emergencies, drug efficacy, dosage management, and response time. For more information, please visit www.aspirebiolabs.com.
Safe Harbor Statement
Certain statements made in this communication are "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as "estimate," "projects," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "would," "should," "future," "propose," "potential," "target," "goal," "objective," "outlook" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Aspire's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Aspire Biopharma Holdings, Inc.
Contact
TraDigital IR
Kevin McGrath
+1-646-418-7002
[email protected]
SOURCE: Aspire Biopharma Holdings, Inc.
View the original press release on ACCESS Newswire
W.Moreno--AT